Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

globenewswire.com
ELTX Elicio Therapeutics announced participation in the Wells Fargo Healthcare Conference. This is a standard corporate announcement and does not inherently indicate positive or negative performance.

Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference BOSTON, Aug. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that management will participate in one-on-one meetings at the upcoming Wells Fargo 21 st Annual Healthcare Conference, taking place September 8-10, 2026, in Boston, MA.

Wells Fargo 21 st Annual Healthcare Conference

Format: One-on-one Meetings

Date: Thursday, September 10, 2026

If you are interested in arranging a 1×1 meeting with management at the conference, please contact your Wells Fargo representative.

About Elicio Therapeutics

Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company advancing next-generation immunotherapies for the treatment of KRAS-driven cancers, including mKRAS-positive pancreatic and colorectal cancers. Elicio intends to build on recent clinical findings in the personalized cancer immunotherapy space to develop effective, off-the-shelf immunotherapies. Elicio’s AMP technology aims to enhance the education, activation, and amplification of cancer-specific T cells relative to conventional immunotherapy strategies, with the goal of promoting durable cancer immunosurveillance in patients. Elicio’s ELI-002 7P lead program is an off-the-shelf immunotherapy candidate targeting the most common KRAS mutations, which drive approximately 25% of all solid tumors. Off-the-shelf immunotherapy approaches have the potential benefits of low cost, rapid, commercial-scale manufacturing, and rapid availability of drug to patients, especially in neo-adjuvant settings and for prophylaxis in high-risk patients, contrary to personalized immunotherapy approaches. Elicio’s pipeline includes additional off-the-shelf therapeutic cancer immunotherapy candidates, including ELI-007 and ELI-008, which target BRAF-driven cancers and p53 hotspot mutations, respectively. For more information, please visit www.elicio.com.

Investor Relations Contact

Brian Ritchie

LifeSci Advisors

(212) 915-2578

britchie@lifesciadvisors.com